Dapagliflozin is a medication used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease. Dapagliflozin was developed by Bristol-Myers Squibb Company.
The API has now reached off-patent status, after being launched in 2008.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Dapagliflozin was exported from India in 2023 , with an average price over the period of $2437 /kg.
The key suppliers were Alembic Pharmaceuticals, with a focus on markets in Asia Pacific.

For enquiries regarding more detailed trade data of Dapagliflozin and many others, contact info@pharmacheminvestor.com